[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

Kidney Cancer Drugs: Market Research Report

April 2012 | 297 pages | ID: K7CA55A588BEN
Global Industry Analysts, Inc

US$ 4,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million.

This report on 'Kidney Cancer Drugs' provides market analytics specifically for the 'Renal Cell Carcinoma' (RCC) market, owing to its predominance among the various types of kidney cancers.

The market for Renal Cell Carcinoma (RCC) drugs is analyzed by the two major drug classes, which include: Multikinase Inhibitors, and Other RCC drug Classes (including Immunomodulators; mTOR inhibitors; and other emerging drug classes).

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2008 through 2017.

The report profiles 19 companies including many key and niche players such as AVEO Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Co., Onyx Pharmaceuticals, Inc., F.Hoffmann-la Roche Ltd., GlaxoSmithKline Plc, Merck-Serono, Novartis AG, Pfizer, Inc., and WILEX AG.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Multikinase Inhibitors
Other RCC drug Classes (including Immunomodulators; mTOR inhibitors; and other emerging drug classes.)

II. EXECUTIVE SUMMARY

1.KIDNEY CANCER – FACTSHEET

2.MARKET OVERVIEW

Market Scenario
Multikinase Inhibitors Dominate the Market
Presently Approved Drugs for the Treatment of Advanced Renal Cell Carcinoma (RCC)
Kidney Cancer Bodes Significant Potential for Targeted Therapies
Leading Kidney Cancer Drugs
Pfizer’s Sutent Tops the RCC Drugs Market

Table 1. Leading Kidney Cancer Drugs Worldwide (2009): Sales for Sutent, Nexavar, Afinitor, Avastin, and Proleukin

GSK’s Votrient Threatens Sutent’s Dominance
Nexavar Dominates Second Line Treatment for RCC

Table 2. Leading Drugs in the Second Line Treatment of RCC (2011): Market Share Breakdown for Nexavar, Torisel, Afinitor, Avastin, and Others (includes corresponding Graph/Chart)

Torisel Leads Third Line Treatment for RCC

Table 3. Leading Drugs in the Third Line Treatment of RCC (2017E): Market Share Breakdown for Afinitor, Axitinib, Avastin, Torisel, and Others (includes corresponding Graph/Chart)

3.KIDNEY CANCER: A GLIMPSE INTO THE DISEASE, CAUSES, SYMPTOMS, AND DIAGNOSIS

Kidney Cancer: Disease Overview
Causes
Symptoms and Signs
Stages
Renal Cell Carcinoma (RCC): The Most Common Kidney Cancer
Types
Symptoms and Signs
Diagnosis

4.KIDNEY CANCER TREATMENT

Surgical Treatment
Targeted Therapies
Multi-kinase Inhibitors
mTOR Inhibitors
Oral Targeted Therapies
Injectable Targeted Therapy
Pros and Cons of Targeted Therapies
Monoclonal Antibodies
Immunomodulators
Aldesleukin (Proleukin®)
Interferon alpha-2 (Roferon-A®)

5.PROFILES OF MAJOR KIDNEY CANCER DRUGS

Sutent (Sunitinib)
Sutent Vs. Interferon-alpha and IFN-alpha therapies
Nexavar (Sorafenib)
Torisel (Temsirolimus)
Votrient (Pazopanib)
Avastin (Bevacizumab)
Afinitor (Everolimus)

6.PIPELINE ANALYSIS

Select Kidney Cancer Pipeline: As of 2010
Select Pipeline Drugs – A Review
Axitinib (Pfizer)
Tivozanib (AVEO Pharmaceuticals)

RENCAREX (WILEX)

TroVax (Oxford BioMedica)

7.CANCER STATISTICS

Cancer Incidence – Statistics on New Cases

Table 4. Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart)
Table 5. Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart)
Table 6. Cancer Incidence in Upper Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart)
Table 7. Cancer Incidence in Lower Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart)
Table 8. Cancer Incidence in High Income Countries by Site: 2009 (includes corresponding Graph/Chart)

8.RECENT INDUSTRY ACTIVITY AND PRODUCT APPROVALS

WILEX Grants Exclusive US Commercialisation Rights for RENCAREX to Prometheus
AVEO Collaborates with Astellas to Develop and Commercialize Tivozanib
Novartis Sells Proleukin US Rights to Prometheus Laboratories
WILEX Announces End Results of REDECT Phase 3 Registration Trial with Redectane®
NICE Rejects Novartis’ Kidney Cancer Drug Everolimus
GlaxoSmithKline Gains Conditional EU Approval for Votrient (pazopanib)
Prometheus and Novartis Enters into Commercialization Agreement
Cipla Launches Soranib Cancer Medicine
Bristol-Myers Squibb Divests Nutrition Business, Mead Johnson Nutrition, to Focus on Biopharma Business
Roche Acquires Genentech
Novartis’ Afinitor® Obtains EC Approval for Advanced RCC Treatment
Novartis Obtains FDA Approval for Afinitor
Roche Receives FDA Approval for Avastin in Combination with Interferon-Alpha for RCC Treatment
Pfizer’s Sutent Obtains Recommendation as First Line Treatment for mRCC
GlaxoSmithKline Receives FDA Approval for Votrient

9.STRATEGIC CORPORATE DEVELOPMENTS AND PRODUCT APPROVALS – A HISTORIC PERSPECTIVE BUILDER

Oxford BioMedica’s TroVax Fails Kidney Cancer Clinical Trial
Genomic Health to Collaborate with Pfizer for New Genomic Test
Roche’s Avastin Bags European Approval for Renal Cancer Treatment
Wyeth’s TORISEL Receives FDA Approval
AstraZeneca’s Novel Cancer Drug, AZD2171, Dubbed Recentin

10.FOCUS ON SELECT GLOBAL PLAYERS

AVEO Pharmaceuticals (US)
Bayer AG (Germany)
Bristol-Myers Squibb Co. (US)
Onyx Pharmaceuticals, Inc. (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline Plc. (UK)
Merck-Serono (Switzerland)
Novartis AG (Switzerland)
Pfizer, Inc. (US)
WILEX AG (Germany)

11.GLOBAL MARKET PERSPECTIVE

Table 9. World Recent Past, Current & Future Analysis for Renal Cell Carcinoma (RCC) Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 10. World 10-Year Perspective for Renal Cell Carcinoma (RCC) Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)
Table 11. World Recent Past, Current & Future Analysis for Multikinase Inhibitors by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 12. World 10-Year Perspective for Multikinase Inhibitors by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)
Table 13. World Recent Past, Current & Future Analysis for Other RCC Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 14. World 10-Year Perspective for Other RCC Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis
Cancer Statistics in the US
Cancer Incidence Statistics

Table 15. New Cancer Cases in the US by Affected Site: 2009
Table 16. New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)
Table 17. New Cancer Cases in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart)

Cancer Mortality Statistics

Table 18. Cancer Related Deaths in the US by Affected Site: 2009
Table 19. Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)
Table 20. Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart)

Kidney Cancer Incidence Rates and Mortality Statistics

Table 21. Kidney Cancer Incidence Rates by Race/Ethnicity per 10,000 Men (includes corresponding Graph/Chart)
Table 22. Kidney Cancer Incidence Rates by Race/Ethnicity Per 10,000 Women (includes corresponding Graph/Chart)
Table 23. Kidney Cancer Mortality Rates by Race/Ethnicity per 10,000 Men (includes corresponding Graph/Chart)
Table 24. Kidney Cancer Mortality Rates by Race/Ethnicity Per 10,000 Women (includes corresponding Graph/Chart)

NCI Funding for Kidney Cancer on the Rise

Table 25. NCI’s Annual Funding on Kidney Cancer Research for Years 2007, 2008 & 2009 (includes corresponding Graph/Chart)
Table 26. Allocation of Funds by Scientific/Research Area (2009) (includes corresponding Graph/Chart)

Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 27. The US Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 28. The US 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

2.CANADA

A. Market Analysis
Cancer Incidence and Mortality Statistics in Canada

Table 29. New Cancer Cases by Type/Site Among Canadian Men (2010) (includes corresponding Graph/Chart)
Table 30. New Cancer Cases by Type/Site Among Canadian Women (2010) (includes corresponding Graph/Chart)
Table 31. Cancer Deaths by Type/Site Among Canadian Men (2010) (includes corresponding Graph/Chart)
Table 32. Cancer Deaths by Type/Site Among Canadian Women (2010) (includes corresponding Graph/Chart)

B. Market Analytics

Table 33. Canadian Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 34. Canadian 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

3.JAPAN

Market Analytics

Table 35. Japanese Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 36. Japanese 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

4.EUROPE

A. Market Analysis
Cancer Statistics in Europe

Table 37. Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart)

Strategic Corporate Developments
B. Market Analytics

Table 38. European Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Geographic Region - France, Germany, Italy, UK and Rest of European Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 39. European 10-Year Perspective for Renal Cell Carcinoma Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of European Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)
Table 40. European Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 41. European 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

4A.FRANCE

Market Analytics

Table 42. French Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 43. French 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

4B.GERMANY

A. Market Analysis
Strategic Corporate Development
Focus on Select Major Players
B. Market Analytics

Table 44. German Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 45. German 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

4C.ITALY

Market Analytics

Table 46. Italian Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 47. Italian 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

4D.THE UNITED KINGDOM

A. Market Analysis
Kidney Cancer Statistics
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 48. The UK Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 49. The UK 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

4E.REST OF EUROPE

A. Market Analysis
Focus on Select Major Players
B. Market Analytics

Table 50. Rest of European Recent Past, Current & Future Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 51. Rest of European 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

5.ASIA-PACIFIC

A. Market Analysis
Cancer Statistics in Asia-Pacific

Table 52. Cancer Incidence in Asia-Oceania by Site: 2009 (includes corresponding Graph/Chart)

Product Launch
B. Market Analytics

Table 53. Asia-Pacific Recent Past, Current & Future Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 54. Asia-Pacific 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

6.REST OF WORLD

Market Analytics

Table 55. Rest of World Recent Past, Current & Future Analysis for Renal Cell Carcinoma Drugs by Drug Class - Multikinase Inhibitors and Others Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 56. Rest of World 10-Year Perspective for Renal Cell Carcinoma Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Multikinase Inhibitors and Others Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 19 (including Divisions/Subsidiaries - 21)
The United States (10)
Canada (1)
Europe (9)
- Germany (3)
- The United Kingdom (3)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (1)

More Publications

Need Help?

Ask a Question

Market Reports

All Categories